MALAT1 downregulation is associated with polycystic ovary syndrome via binding with MDM2 and repressing P53 degradation - PubMed (original) (raw)

MALAT1 downregulation is associated with polycystic ovary syndrome via binding with MDM2 and repressing P53 degradation

Yan Li et al. Mol Cell Endocrinol. 2022.

Abstract

Polycystic ovary syndrome (PCOS) is a metabolic disorder of the reproductive system that affects 6-20% women of reproductive age. Multiple coding and non-coding genes were found to be affected in patients with PCOS, including MALAT1, an 8.7 kb long non-coding RNA. MALAT1 has been found to interact with miRNAs in granulosa cells (GCs); however, its binding proteins in GCs are still unknown. In this study, MALAT1 binding proteins in primary GCs were recruited by RNA antisense purification (RAP) assay and identified by mass spectrometry. The interaction between MALAT1 and proteins was examined by the PAR-CLIP assay and immunofluorescence. Functional studies were performed using the human granulosa-like tumor cell line (KGN) and primary granulosa cells. We identified that MALAT1 interacted with MDM2 and PARP1 in the cell nucleus. MDM2 binds to the 3' segment of MALAT1, containing the ENE domain through the ring finger domain. Knockdown of MALAT1 in GCs increased p53 protein levels by repressing p53 ubiquitination and degradation. MALAT1 promoted the binding between P53 and MDM2, which further boosted P53 proteasome dependent degradation. Knockdown of MALAT1 in KGN cells and primary GCs increased apoptosis and reduced proliferation.

Keywords: MALAT1; Non-coding RNA; Polycystic ovary syndrome; Ubiquitination.

PubMed Disclaimer

Cited by

Current Advances in Cellular Approaches for Pathophysiology and Treatment of Polycystic Ovary Syndrome.
Tsai YR, Liao YN, Kang HY. Tsai YR, et al. Cells. 2023 Aug 31;12(17):2189. doi: 10.3390/cells12172189. Cells. 2023. PMID: 37681921 Free PMC article. Review.
Effect of lncRNA MALAT1 on the Granulosa Cell Proliferation and Pregnancy Outcome in Patients With PCOS.
Tu M, Wu Y, Wang F, Huang Y, Qian Y, Li J, Lv P, Ying Y, Liu J, Liu Y, Zhang R, Zhao W, Zhang D. Tu M, et al. Front Endocrinol (Lausanne). 2022 Apr 27;13:825431. doi: 10.3389/fendo.2022.825431. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35573984 Free PMC article.
Evaluation of the p53 pathway in polycystic ovarian syndrome pathogenesis and apoptosis enhancement in human granulosa cells through transcriptome data analysis.
Zanjirband M, Hodayi R, Safaeinejad Z, Nasr-Esfahani MH, Ghaedi-Heydari R. Zanjirband M, et al. Sci Rep. 2023 Jul 19;13(1):11648. doi: 10.1038/s41598-023-38340-1. Sci Rep. 2023. PMID: 37468508 Free PMC article.
Modulation of the Inflammatory Response in Polycystic Ovary Syndrome (PCOS)-Searching for Epigenetic Factors.
Szukiewicz D, Trojanowski S, Kociszewska A, Szewczyk G. Szukiewicz D, et al. Int J Mol Sci. 2022 Nov 24;23(23):14663. doi: 10.3390/ijms232314663. Int J Mol Sci. 2022. PMID: 36498989 Free PMC article. Review.
Silencing the long noncoding RNA MALAT1 inhibits vitreous-induced epithelial-mesenchymal transition in RPE cells by regulating the PDGFRs/AKT axis.
Yang G, Huang Y, Li D, Tang J, Li W, Huang X. Yang G, et al. Int Ophthalmol. 2024 Sep 4;44(1):363. doi: 10.1007/s10792-024-03295-3. Int Ophthalmol. 2024. PMID: 39227412

MALAT1 downregulation is associated with polycystic ovary syndrome via binding with MDM2 and repressing P53 degradation - PubMed (original) (raw)